Maladaptive modulations of nlrp3 inflammasome and cardioprotective pathways are involved in diet-induced exacerbation of myocardial ischemia/reperfusion injury in mice

Oxidative Medicine and Cellular Longevity

Volumn 2016, Issue , 2016, Pages

  Mastrocola, Raffaella ^a   Collino, Massimo ^a   Penna, Claudia ^a   Nigro, Debora ^a   Chiazza, Fausto ^a   Fracasso, Veronica ^a   Tullio, Francesca ^a   Alloatti, Giuseppe ^a,b   Pagliaro, Pasquale ^a   Aragno, Manuela ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b National Institute for Cardiovascular Research   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOLOGY; CHEMICAL ACTIVATION; CROSSTALK; FATTY ACIDS; METABOLISM;

CARDIO-VASCULAR DISEASE; DIETARY MANIPULATION; HIGH-FRUCTOSE DIETS; HYPOXIA-INDUCIBLE FACTORS; ISCHEMIA/REPERFUSION; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; OXIDATIVE METABOLISM;

MAMMALS;

CHOLESTEROL; CRYOPYRIN; FAT; FRUCTOSE; GLUCOSE; HYPOXIA INDUCIBLE FACTOR 2ALPHA; INFLAMMASOME; INSULIN; INTERLEUKIN 1BETA CONVERTING ENZYME; LACTATE DEHYDROGENASE; MYOSIN HEAVY CHAIN ALPHA; MYOSIN HEAVY CHAIN BETA; TRIACYLGLYCEROL; CARDIOTONIC AGENT; CARRIER PROTEIN; GLUCOSE TRANSPORTER 4; HIF-2 PROTEIN, MOUSE; INSULIN RECEPTOR SUBSTRATE; IRS2 PROTEIN, MOUSE; NLRP3 PROTEIN, MOUSE; TRANSCRIPTION FACTOR;

AEROBIC METABOLISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET; DISEASE EXACERBATION; DOWN REGULATION; ENZYME ACTIVATION; GLUCOSE BLOOD LEVEL; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HIGH FAT HIGH FRUCTOSE DIET; INSULIN BLOOD LEVEL; LIPID PEROXIDATION; LIPID STORAGE; MALE; MITOCHONDRION; MOUSE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PROTEIN EXPRESSION; REPERFUSION INJURY; SIGNAL TRANSDUCTION; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; ADVERSE EFFECTS; ANIMAL; C57BL MOUSE; CARDIAC MUSCLE; CELL SURVIVAL; COMPLICATION; DISEASE COURSE; HEART INFARCTION; LIPID DIET; METABOLISM; MYOCARDIAL ISCHEMIA REPERFUSION INJURY; PATHOLOGY; PROTEIN TRANSPORT; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; CARDIOTONIC AGENTS; CARRIER PROTEINS; CELL SURVIVAL; DIET; DIET, HIGH-FAT; DISEASE PROGRESSION; GLUCOSE TRANSPORTER TYPE 4; INFLAMMASOMES; INSULIN RECEPTOR SUBSTRATE PROTEINS; L-LACTATE DEHYDROGENASE; LIPID PEROXIDATION; MALE; MICE, INBRED C57BL; MITOCHONDRIA; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; NLR FAMILY, PYRIN DOMAIN-CONTAINING 3 PROTEIN; OXIDATIVE STRESS; PROTEIN TRANSPORT; TRANSCRIPTION FACTORS;

EID: 84953924429     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2016/3480637     Document Type: Article

References (47)

1. L. Pulakat, V. G. DeMarco, S. Ardhanari et al., "Adaptive mechanisms to compensate for overnutrition-induced cardiovascular abnormalities," American Journal of Physiology-Regulatory Integrative and Comparative Physiology, vol. 301, no. 4, pp. R885-R895, 2011.
2. G. D. Thakker, N. G. Frangogiannis, P. T. Zymek et al., "Increasedmyocardial susceptibility to repetitive ischemia with high-fat diet-induced obesity," Obesity, vol. 16, no. 12, pp. 2593-2600, 2008.
3. I. Wensley, K. Salaveria, A. C. Bulmer, D. G. Donner, and E. F. Du Toit, "Myocardial structure, function and ischaemic tolerance in a rodent model of obesity with insulin resistance," Experimental Physiology, vol. 98, no. 11, pp. 1552-1564, 2013.
4. G. D. Lopaschuk, J. R. Ussher, C. D. L. Folmes, J. S. Jaswal, and W. C. Stanley, "Myocardial fatty acid metabolism in health and disease," Physiological Reviews, vol. 90, no. 1, pp. 207-258, 2010.
5. B. Vandanmagsar, Y.-H. Youm, A. Ravussin et al., "The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance," Nature Medicine, vol. 17, no. 2, pp. 179-189, 2011.
6. M. Collino, E. Benetti, M. Rogazzo et al., "Reversal of the deleterious effects of chronic dietary HFCS-55 intake by PPAR-δ agonism correlates with impaired NLRP3 inflammasome activation," Biochemical Pharmacology, vol. 85, no. 2, pp. 257-264, 2013.
7. E. Mezzaroma, S. Toldo, D. Farkas et al., "The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse," Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 49, pp. 19725-19730, 2011.
8. A. A. Wanderer, "Ischemic-reperfusion syndromes: biochemical and immunologic rationale for IL-1 targeted therapy," Clinical Immunology, vol. 128, no. 2, pp. 127-132, 2008.
9. C. J. Tack, R. Stienstra, L. A. B. Joosten, and M. G. Netea, "Inflammation links excess fat to insulin resistance: the role of the interleukin-1 family," Immunological Reviews, vol. 249, no. 1, pp. 239-252, 2012.
10. M. Kawaguchi, M. Takahashi, T. Hata et al., "Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury," Circulation, vol. 123, no. 6, pp. 594-604, 2011.
11. J. Fuentes-Antras, A. M. Ioan, J. Tuñon, J. Egido, and O. Lorenzo, "Activation of toll-like receptors and inflammasome complexes in the diabetic cardiomyopathy-associated inflammation," International Journal of Endocrinology, vol. 2014, Article ID 847827, 10 pages, 2014.
12. R. Zhou, A. Tardivel, B. Thorens, I. Choi, and J. Tschopp, "Thioredoxin-interacting protein links oxidative stress to inflammasome activation," Nature Immunology, vol. 11, no. 2, pp. 136-140, 2010.
13. M. Aragno, R. Mastrocola, C. Ghé et al., "Obestatin induced recovery of myocardial dysfunction in type 1 diabetic rats: underlying mechanisms," Cardiovascular Diabetology, vol. 11, article 129, 2012.
14. P. Pagliaro, F. Moro, F. Tullio, M.-G. Perrelli, and C. Penna, "Cardioprotective pathways during reperfusion: focus on redox signaling and other modalities of cell signaling," Antioxidants and Redox Signaling, vol. 14, no. 5, pp. 833-850, 2011.
15. D. J. Hausenloy and D. M. Yellon, "Newdirections forprotecting the heart against ischaemia-reperfusion injury: targeting the Reperfusion Injury SalvageKinase (RISK)-pathway," Cardiovascular Research, vol. 61, no. 3, pp. 448-460, 2004.
16. P. Ferdinandy, D. J. Hausenloy, G. Heusch, G. F. Baxter, and R. Schulz, "Interaction of risk factors, comorbidities, and comedications with ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning," Pharmacological Reviews, vol. 66, no. 4, pp. 1142-1174, 2014.
17. J. Hyvärinen, I. E. Hassinen, R. Sormunen et al., "Hearts of hypoxia-inducible factor prolyl 4-hydroxylase-2 hypomorphic mice show protection against acute ischemia-reperfusion injury," The Journal of Biological Chemistry, vol. 285, no. 18, pp. 13646-13657, 2010.
18. J. S. Jürgensen, C. Rosenberger, M. S. Wiesener et al., "Persistent induction of HIF-1α and-2α in cardiomyocytes and stromal cells of ischemic myocardium," The FASEB Journal, vol. 18, no. 12, pp. 1415-1417, 2004.
19. J. B. Pampin, S. A. Garcia Rivero, X. L. Otero Cepeda, A. V. Boquete, J. F. Vila, and R. H. Fonseca, "Immunohistochemical expression of HIF-1α in response to earlymyocardial ischemia," Journal of Forensic Sciences, vol. 51, no. 1, pp. 120-124, 2006.
20. S. H. Lee, P. L. Wolf, R. Escudero, R. Deutsch, S. W. Jamieson, and P. A. Thistlethwaite, "Early expression of angiogenesis factors in acute myocardial ischemia and infarction," The New England Journal of Medicine, vol. 342, no. 9, pp. 626-633, 2000.
21. J. Wu, P. Chen, Y. Li et al., "HIF-1α in heart: protective mechanisms," The American Journal of Physiology-Heart and Circulatory Physiology, vol. 305, no. 6, pp. H821-H828, 2013.
22. E. B. Rankin, J. Rha, M. A. Selak et al., "Hypoxia-inducible factor regulates hepatic lipid metabolism," Molecular and Cellular Biology, vol. 29, no. 16, pp. 4527-4538, 2009.
23. C. Penna, M. Brancaccio, F. Tullio et al., "Overexpression of the muscle-specific protein, melusin, protects from cardiac ischemia/reperfusion injury," Basic Research in Cardiology, vol. 109, article 418, 2014.
24. M. Aragno, R. Mastrocola, C. Medana et al., "Oxidative stressdependent impairment of cardiac-specific transcription factors in experimental diabetes," Endocrinology, vol. 147, no. 12, pp. 5967-5974, 2006.
25. M. Rajesh, S. Batkai, M. Kechrid et al., "Cannabinoid 1 receptor promotes cardiac dysfunction, oxidative stress, inflammation, and fibrosis in diabetic cardiomyopathy," Diabetes, vol. 61, no. 3, pp. 716-727, 2012.
26. J. E. Schaffer, "Lipotoxicity: when tissues overeat," Current Opinion in Lipidology, vol. 14, no. 3, pp. 281-287, 2003.
27. R. Salie, B. Huisamen, and A. Lochner, "High carbohydrate and high fat diets protect the heart against ischaemia/reperfusion injury," Cardiovascular Diabetology, vol. 13, article 109, 2014.
28. Y. Xu, L.-L. Ma, C. Zhou et al., "Hypercholesterolemic myocardium is vulnerable to ischemia-reperfusion injury and refractory to sevoflurane-induced protection," PLoS ONE, vol. 8, no. 10, Article ID e76652, 2013.
29. D. J. Hausenloy and D. M. Yellon, "Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection," Heart Failure Reviews, vol. 12, no. 3-4, pp. 217-234, 2007.
30. N. Ghaboura, S. Tamareille, P.-H. Ducluzeau et al., "Diabetes mellitus abrogates erythropoietin-induced cardioprotection against ischemic-reperfusion injury by alteration of the RISK/GSK-3β signaling," Basic Research in Cardiology, vol. 106, no. 1, pp. 147-162, 2011.
31. M. Collino, E. Benetti, M. Rogazzo et al., "A non-erythropoietic peptide derivative of erythropoietin decreases susceptibility to diet-induced insulin resistance in mice," British Journal of Pharmacology, vol. 171, no. 24, pp. 5802-5815, 2014.
32. L.-L. Ma, F.-J. Zhang, L.-B. Qian et al., "Hypercholesterolemia blocked sevoflurane-induced cardioprotection against ischemia-reperfusion injury by alteration of theMG53/RISK/GSK3β signaling," International Journal ofCardiology, vol. 168, no. 4, pp. 3671-3678, 2013.
33. I. Kojima, T. Tanaka, R. Inagi et al., "Protective role of hypoxiainducible factor-2α against ischemic damage and oxidative stress in the kidney," Journal of theAmerican Society of Nephrology, vol. 18, no. 4, pp. 1218-1226, 2007.
34. S.-G. Ong and D. J. Hausenloy, "Hypoxia-inducible factor as a therapeutic target for cardioprotection," Pharmacology and Therapeutics, vol. 136, no. 1, pp. 69-81, 2012.
35. C. M. Taniguchi, E. C. Finger, A. J. Krieg et al., "Cross-talk between hypoxia and insulin signaling through Phd3 regulates hepatic glucose and lipid metabolism and ameliorates diabetes," Nature Medicine, vol. 19, no. 10, pp. 1325-1330, 2013.
36. K. Wei, S. M. Piecewicz, L. M. McGinnis et al., "A liver Hif-2α-Irs2 pathway sensitizes hepatic insulin signaling and is modulated by Vegf inhibition," Nature Medicine, vol. 19, no. 10, pp. 1331-1337, 2013.
37. E. Benetti, F. Chiazza, N. S. A. Patel, and M. Collino, "The NLRP3 inflammasome as a novel player of the intercellular crosstalk in metabolic disorders," Mediators of Inflammation, vol. 2013, Article ID 678627, 9 pages, 2013.
38. S. Toldo, E. Mezzaroma, A. G. Mauro, F. Salloum, B. W. Van Tassell, and A. Abbate, "The inflammasome in myocardial injury and cardiac remodeling," Antioxidants and Redox Signaling, vol. 22, no. 13, pp. 1146-1161, 2015.
39. G. H. Goossens, E. E. Blaak, R. Theunissen et al., "Expression of NLRP3 inflammasome and T cell population markers in adipose tissue are associated with insulin resistance and impaired glucosemetabolism in humans,"Molecular Immunology, vol. 50, no. 3, pp. 142-149, 2012.
40. H.-M. Lee, J.-J. Kim, H. J. Kim, M. Shong, B. J. Ku, and E.-K. Jo, "UpregulatedNLRP3 inflammasome activation in patients with type 2 diabetes," Diabetes, vol. 62, no. 1, pp. 194-204, 2013.
41. Y. Liu, K. Lian, L. Zhang et al., "TXNIP mediates NLRP3 inflammasome activation in cardiac microvascular endothelial cells as a novel mechanism in myocardial ischemia/reperfusion injury," Basic Research in Cardiology, vol. 109, no. 5, article 415, 2014.
42. C. Marchetti, J. Chojnacki, S. Toldo et al., "A novel pharmacologic inhibitor of the NLRP3 inflammasome limits myocardial injury after ischemia-reperfusion in the mouse," Journal of Cardiovascular Pharmacology, vol. 63, no. 4, pp. 316-322, 2014.
43. M. Scortegagna, K. Ding, Y. Oktay et al., "Multiple organ pathology, metabolic abnormalities and impaired homeostasis of reactive oxygen species in Epas1-/- mice," Nature Genetics, vol. 35, no. 4, pp. 331-340, 2003.
44. L. Chen, R. Na, E. Boldt, and Q. Ran, "NLRP3 inflammasome activation by mitochondrial reactive oxygen species plays a key role in long-term cognitive impairment induced by paraquat exposure," Neurobiology of Aging, vol. 36, no. 9, pp. 2533-2543, 2015.
45. F. Usui, K. Shirasuna, H. Kimura et al., "Inflammasome activation by mitochondrial oxidative stress in macrophages leads to the development of angiotensin II-induced aortic aneurysm," Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 35, no. 1, pp. 127-136, 2014.
46. Y. Zhuang, M. Yasinta, C. Hu et al., "Mitochondrial dysfunction confers albumin-inducedNLRP3 inflammasome activation and renal tubular injury," The American Journal of Physiology-Renal Physiology, vol. 308, no. 8, pp. F857-F866, 2015.
47. A. Kauppinen, H. Niskanen, T. Suuronen, K. Kinnunen, A. Salminen, and K. Kaarniranta, "Oxidative stress activates NLRP3 inflammasomes in ARPE-19 cells-implications for agerelatedmacular degeneration (AMD)," Immunology Letters, vol. 147, no. 1-2, pp. 29-33, 2012.